HBeAg阳性慢性乙型肝炎抗病毒治疗药物的比较  

Comparative Study on Anti-HBV Drugs in HBeAg Positive Chronic Hepatitis B

作　　者：张文坚[1,2] 谭德明[2] 龚环宇[1] 

机构地区：[1]中南大学湘雅三医院感染病科,湖南长沙410013 [2]中南大学湘雅医院感染病科,湖南长沙410008

出　　处：《医学与哲学（B）》2008年第11期37-39,61,共4页Medicine & Philosophy(B)

摘　　要：抗病毒治疗是慢性乙型肝炎治疗的关键。目前抗乙型肝炎病毒(HBV)药物主要有两大类,本文从抗病毒治疗的适应症、禁忌症、治疗效果、耐药性、依从性和治疗费用等方面对现有抗HBV药物进行了比较和分析,认为在选择抗HBV药物时,应遵循规范化与个体化相结合的原则,在患者能承受的费用范围内,尽量选择抗病毒作用强、耐药率低、耐受性良好的药物。Antiviral treatment is the key therapy of chronic hepatitis B. Currently there are two major types of approved anti --HBV drugs, and they are compared in the aspects of indications and contraindications of anti--HBV therapy, therapeu tic efficacy, drug resistance, compliance and expenditure in this paper. When we choose anti--HBV drugs, the principle of the combination of normalization and individualization should follow, and we should select the drug with strong antivirus effect, low resistance rate, and good tolerance.

关 键 词：慢性乙型肝炎 抗病毒治疗 干扰素类 核苷(酸)类似物 

分 类 号：R512.62[医药卫生—内科学]